Etop Ibcsg Partners Foundation
Clinical trials sponsored by Etop Ibcsg Partners Foundation, explained in plain language.
-
Could a lung cancer drug designed for one mutation work for another?
Disease control TerminatedThis phase II trial tests whether alectinib, a drug typically used for ALK-positive lung cancer, can shrink tumors or control disease in people with advanced non-small cell lung cancer that has a RET gene rearrangement and has progressed after prior treatment. Participants take a…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Blood protein clues could personalize breast cancer care
Knowledge-focused TerminatedThis study investigates whether levels of certain blood proteins—VEGF, soluble HER2, and VCAM-1—change over time in women with hormone-insensitive breast cancer. It compares women who receive maintenance chemotherapy with those who do not, and also looks at whether these protein …
Phase: NA • Sponsor: ETOP IBCSG Partners Foundation • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC